U.S. News Room
Daiichi Sankyo, Inc. Launches CommitmentsinPainCare.com
November 20, 2017
Basking Ridge, N.J. (November 20, 2017) – Daiichi Sankyo, Inc. today announced the launch of CommitmentsinPainCare.com, a new website designed to help inform discussions between patients, caregivers and healthcare professionals about integrated approaches to pain management, prevention of diversion of prescription opioid medications and the signs of potential abuse or addiction associated with opioid medications. The website is the latest of several initiatives Daiichi Sankyo is introducing as part of Commitments in Pain Care, a program focused on education and awareness about responsible pain management.
“Acute and chronic pain impacts a substantial number of individuals in the United States. When alternative treatment options are inadequate, pain management may require the use of prescription opioid medications, which are associated with many serious risks including diversion, misuse, abuse and addiction. This translates into a myriad of conversations between patients and their healthcare providers about effectively and responsibly managing pain that meets individual needs,” said Ken Keller, President, Administrative and Commercial, Daiichi Sankyo, Inc. “We established CommitmentsinPainCare.com to help with these complex discussions as part of our commitment to people living with pain and those involved in their care.”
Key features of CommitmentsinPainCare.com include:
Information about adopting a balanced approach to pain management through a variety of interventions and strategies, as well as facts about the opioid crisis and efforts underway to effectively balance pain relief and the risks associated with opioid use.
Resources for patients and caregivers that focus on pain treatment, such as questions to ask before starting an opioid, tips for proper storage and safe disposal of medications, information on misuse, abuse and addiction and warning signs, as well as substance abuse treatment assistance.
Resources for healthcare professionals including current pain management and prescribing guidelines, tools for assessing abuse and addiction risk prior to prescribing opioids, and guidance for recognizing misuse, abuse and addiction.
“People living with pain are in need of resources and support to help manage their condition,” said Paul Gileno, President and Founder, U.S. Pain Foundation. “I am encouraged that Daiichi Sankyo is being an example for industry by taking responsibility to provide key information to patients through websites such as CommitmentsinPainCare.com, which makes resources available to empower and prepare them for much needed conversations with their healthcare providers.”
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com.
About Commitments in Pain Care
Commitments in Pain Care is a program that reflects Daiichi Sankyo, Inc.’s dedication to responsibly bringing innovative medicines to patients in pain and being a part of the solution to controlled substance abuse. The program is designed to engage and educate key stakeholders around responsible pain management, including patients and caregivers, healthcare professionals, advocates, employees and others. Pain management may require the appropriate use of prescription medicines including controlled substances such as opioids, and these medicines may be associated with many safety concerns including diversion, misuse, abuse, addiction, or overdose. Commitments in Pain Care underscores the Company’s dedication to undertaking the marketing and distribution of its pain medicines, as well as engagement with stakeholders, with a great sense of responsibility and professionalism. To learn more about Commitments in Pain Care, please visit: www.CommitmentsinPainCare.com
Daiichi Sankyo, Inc.